{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:47:46Z","timestamp":1789084066148,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cgh.2025.07.028","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T19:05:29Z","timestamp":1753729529000},"page":"772-783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Upadacitinib Maintenance Therapy in Crohn\u2019s Disease: Final Results From the Randomized Phase 3 U-ENDURE Study"],"prefix":"10.1016","volume":"24","author":[{"given":"Remo","family":"Panaccione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Regueiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Atreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Broide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"van Bodegraven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Dubcenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqian","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"van Haaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel I.","family":"Anyanwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-6902","authenticated-orcid":false,"given":"Julian","family":"Pan\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.07.028_bib1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1046\/j.1365-2036.2002.01323.x","article-title":"The quality of life in patients with Crohn\u2019s disease","volume":"16","author":"Cohen","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.07.028_bib2","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/ibd.21580","article-title":"A population-based study of fatigue and sleep difficulties in inflammatory bowel disease","volume":"17","author":"Graff","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2025.07.028_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/gut.2011.239301.434","article-title":"Patients with Crohn\u2019s disease report high levels of fatigue during a symptomatic disease flare","volume":"60","author":"Lamb","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.07.028_bib4","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.07.028_bib5","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.07.028_bib8","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.07.028_bib9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.07.028_bib10","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.07.028_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"10S","key":"10.1016\/j.cgh.2025.07.028_bib12","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.14309\/01.ajg.0000859500.54469.44","article-title":"S715 Clinical and endoscopic improvements with risankizumab induction and maintenance dosing vs placebo are observed irrespective of number of prior failed biologics","volume":"117","author":"Ferrante","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.07.028_bib13","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.cgh.2024.02.026","article-title":"Upadacitinib achieves clinical and endoscopic outcomes in Crohn\u2019s disease regardless of prior biologic exposure","volume":"22","author":"Peyrin-Biroulet","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Supplement_1","key":"10.1016\/j.cgh.2025.07.028_bib14","doi-asserted-by":"crossref","first-page":"i510","DOI":"10.1093\/ecco-jcc\/jjac190.0509","article-title":"P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn\u2019s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies","volume":"17","author":"Vermeire","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"Supplement_1","key":"10.1016\/j.cgh.2025.07.028_bib15","doi-asserted-by":"crossref","first-page":"i22","DOI":"10.1093\/ecco-jcc\/jjac190.0017","article-title":"OP17 Upadacitinib improves endoscopic outcomes in patients with moderate to severely active Crohn\u2019s disease irrespective of previous failure to respond to biologics or conventional therapies","volume":"17","author":"Feagan","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"Supplement_1","key":"10.1016\/j.cgh.2025.07.028_bib16","doi-asserted-by":"crossref","first-page":"i759","DOI":"10.1093\/ecco-jcc\/jjac190.0760","article-title":"P630 Upadacitinib improves clinical outcomes in patients with moderate to severely active Crohn\u2019s disease irrespective of previous failure to respond to biologics or conventional therapies","volume":"17","author":"Schreiber","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.07.028_bib17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cgh.2024.08.032","article-title":"Efficacy and safety of upadacitinib for perianal fistulizing Crohn\u2019s disease: a post hoc analysis of 3 phase 3 trials","volume":"23","author":"Colombel","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10S","key":"10.1016\/j.cgh.2025.07.028_bib18","doi-asserted-by":"crossref","first-page":"S887","DOI":"10.14309\/01.ajg.0000954280.83972.54","article-title":"S1160 Corticosteroid-sparing effect of upadacitinib in patients with moderately-to-severely active Crohn\u2019s disease","volume":"118","author":"Dubinsky","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.07.028_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.cgh.2025.07.028_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525006433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525006433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T07:16:48Z","timestamp":1779607008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525006433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1542356525006433"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.07.028","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upadacitinib Maintenance Therapy in Crohn\u2019s Disease: Final Results From the Randomized Phase 3 U-ENDURE Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}